CASI Pharmaceuticals Company Profile (NASDAQ:CASI)

About CASI Pharmaceuticals

CASI Pharmaceuticals logoCASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CASI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.15
  • 50 Day Moving Average: $1.09
  • 200 Day Moving Average: $1.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.23
  • P/E Growth: 0.00
  • Market Cap: $56.88M
  • Outstanding Shares: 49,457,000
  • Beta: 1.68
Additional Links:
Companies Related to CASI Pharmaceuticals:

Analyst Ratings

Consensus Ratings for CASI Pharmaceuticals (NASDAQ:CASI) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (160.87% upside)

Analysts' Ratings History for CASI Pharmaceuticals (NASDAQ:CASI)
Show:
DateFirmActionRatingPrice TargetDetails
3/29/2016HC WainwrightReiterated RatingBuyView Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2016        
8/15/2016Q2($0.04)($0.08)ViewN/AView Earnings Details
5/13/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
3/28/2016Q415($0.03)($0.05)ViewN/AView Earnings Details
11/13/2015Q315($0.07)($0.05)ViewN/AView Earnings Details
8/14/2015Q215($0.06)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.07)ViewN/AView Earnings Details
8/14/2014Q214($0.06)ViewN/AView Earnings Details
5/15/2014Q114($0.05)($0.05)ViewN/AView Earnings Details
3/21/2014Q413($0.05)$0.67 millionViewN/AView Earnings Details
11/13/2013Q3($0.05)($0.05)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.07)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.02)$1.93 million$0.67 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CASI Pharmaceuticals (NASDAQ:CASI)
Current Year EPS Consensus Estimate: $-0.16 EPS
Next Year EPS Consensus Estimate: $-0.22 EPS

Dividends

Dividend History for CASI Pharmaceuticals (NASDAQ:CASI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CASI Pharmaceuticals (NASDAQ:CASI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/24/2016Byte Ltd SparkleMajor ShareholderBuy3,753,855$1.19$4,467,087.45View SEC Filing  
3/7/2016China Growth Fund Idg-Accel IIMajor ShareholderBuy972,708$2.40$2,334,499.20View SEC Filing  
1/19/2016Cynthia W. HuCOOBuy16,800$0.72$12,096.00View SEC Filing  
1/19/2016Ken RenCEOBuy15,000$0.73$10,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CASI Pharmaceuticals (NASDAQ:CASI)
DateHeadline
reuters.com logoBRIEF-Casi Pharmaceuticals Q2 loss per share $0.08 (NASDAQ:CASI)
www.reuters.com - August 16 at 10:35 AM
streetinsider.com logoCASI Pharma (CASI) Reports ENMD-2076 Phase 2 Met Stage 1 Endpoint in FLC (NASDAQ:CASI)
www.streetinsider.com - August 16 at 10:35 AM
finance.yahoo.com logo7:01 am CASI Pharma announces that its Phase 2 trial of ENMD-2076 in fibrolamellar carcinoma (FLC (NASDAQ:CASI)
finance.yahoo.com - August 16 at 10:35 AM
publicnow.com logoCASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma (NASDAQ:CASI)
www.publicnow.com - August 16 at 10:35 AM
biz.yahoo.com logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:CASI)
biz.yahoo.com - August 15 at 11:19 AM
publicnow.com logoCASI Pharmaceuticals Reports Second Quarter 2016 Financial Results (NASDAQ:CASI)
www.publicnow.com - August 15 at 11:19 AM
News IconRecent research into the metastatic breast cancer - pipeline review, H1 2016 just published (NASDAQ:CASI)
www.whatech.com - July 8 at 4:04 PM
finance.yahoo.com logoGlobal Metastatic Breast Cancer Pipeline Report 2016 - Pipeline Review of 128 Companies & Drug Profiles - Research and Markets (NASDAQ:CASI)
finance.yahoo.com - July 8 at 4:04 PM
News IconSupervisors discuss jail population (NASDAQ:CASI)
qctimes.com - July 1 at 9:14 PM
News IconMcAlester Man Facing Manslaughter Charge After Tulsa Crash (NASDAQ:CASI)
www.news9.com - July 1 at 9:14 PM
News IconPuerto Rico impone moratoria a deuda de casi 2.000 millones (NASDAQ:CASI)
www.oaoa.com - July 1 at 9:14 PM
News IconBartlesville Boy Learns He's Cancer-Free In Viral Video (NASDAQ:CASI)
www.newson6.com - July 1 at 9:14 PM
streetinsider.com logoForm 4 CASI Pharmaceuticals, For: Jun 24 Filed by: Shong Hugo (NASDAQ:CASI)
www.streetinsider.com - July 1 at 9:14 PM
News IconEmergency app Casi targets Gauteng (NASDAQ:CASI)
mybroadband.co.za - July 1 at 9:14 PM
biz.yahoo.com logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities (NASDAQ:CASI)
biz.yahoo.com - June 27 at 4:47 PM
News IconTop 10 Orange is the New Black moments (NASDAQ:CASI)
newsinfilm.com - June 18 at 8:42 AM
finance.yahoo.com logoCASI: Company Announces Positive Phase II Data on ENMD-2076 in Patients with OCCC At ASCO (NASDAQ:CASI)
finance.yahoo.com - June 13 at 11:18 AM
publicnow.com logoCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 (NASDAQ:CASI)
www.publicnow.com - June 12 at 11:29 PM
biz.yahoo.com logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a (NASDAQ:CASI)
biz.yahoo.com - June 3 at 4:47 PM
publicnow.com logoCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Cle (NASDAQ:CASI)
www.publicnow.com - June 1 at 7:13 AM
finance.yahoo.com logoCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC) (NASDAQ:CASI)
finance.yahoo.com - June 1 at 7:00 AM
realistinvestor.com logoAnalysts Set 1-Year Price Target Of $3.75 On CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock - RealistInvestor.com (NASDAQ:CASI)
www.realistinvestor.com - May 29 at 7:30 PM
investornewswire.com logoCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Impact Score At 0 - Investor Newswire (NASDAQ:CASI)
www.investornewswire.com - May 29 at 10:52 AM
investornewswire.com logoHold Calls Count For CASI Pharmaceuticals, Inc. (NASDAQ:CASI) At 0 - Investor Newswire (NASDAQ:CASI)
www.investornewswire.com - May 28 at 7:33 PM
News IconCasi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorted Shares Increased 16.67% After Market Selling - Wall Street Hints and News (NASDAQ:CASI)
hintsnewsnetwork.com - May 24 at 11:37 AM
finance.yahoo.com logoCASI PHARMACEUTICALS, INC. Financials (NASDAQ:CASI)
finance.yahoo.com - May 21 at 1:04 PM
News IconInsiders Are Buying CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Wall Street Hints and News (NASDAQ:CASI)
hintsnewsnetwork.com - May 20 at 11:28 AM
prnewswire.com logoCASI Pharmaceuticals Reports First Quarter 2016 Financial Results - PR Newswire (press release) (NASDAQ:CASI)
www.prnewswire.com - May 13 at 7:54 PM
4-traders.com logoCASI PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (form 8-K) (NASDAQ:CASI)
www.4-traders.com - May 13 at 7:54 PM
publicnow.com logoCASI Pharmaceuticals Reports First Quarter 2016 Financial Results (NASDAQ:CASI)
www.publicnow.com - May 13 at 7:18 AM
prnewswire.com logoCASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For ... - PR Newswire (press release) (NASDAQ:CASI)
www.prnewswire.com - May 12 at 8:02 PM
publicnow.com logoCASI PHARMACEUTICALS RECEIVES APPROVAL FROM CFDA TO CONDUCT PHASE 2 CLINICAL TRIAL (NASDAQ:CASI)
www.publicnow.com - May 12 at 7:27 AM
finance.yahoo.com logoCASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) (NASDAQ:CASI)
finance.yahoo.com - May 12 at 7:00 AM
News IconCasi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorts Decreased by 20.33% After Short Covering - B.O.D.Y Confidential (NASDAQ:CASI)
www.bodyconfidential.com - May 9 at 7:47 PM
kcregister.com logoBiotech Gainers: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), NeuroDerm Ltd. (NASDAQ:NDRM), Fortress Biotech, Inc ... - KC Register (NASDAQ:CASI)
www.kcregister.com - April 20 at 8:15 PM
kcregister.com logoStocks to Watch: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Gerdau S.A. (NYSE:GGB), JinkoSolar Holding Co., Ltd ... - KC Register (NASDAQ:CASI)
www.kcregister.com - April 18 at 8:57 PM
reuters.com logoBRIEF-James Goldschmidt joins CASI Pharmaceuticals as vice president of business development - Reuters (NASDAQ:CASI)
www.reuters.com - April 18 at 8:57 PM
prnewswire.com logoJames E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development - PR Newswire (press release) (NASDAQ:CASI)
www.prnewswire.com - April 18 at 8:57 PM
publicnow.com logoJames E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development (NASDAQ:CASI)
www.publicnow.com - April 18 at 7:21 AM
investornewswire.com logoCASI Pharmaceuticals, Inc. (NASDAQ:CASI)'s 52-Week Price Target At $3.00 - Investor Newswire (NASDAQ:CASI)
www.investornewswire.com - April 15 at 8:18 PM
investornewswire.com logoCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Reported Comprehensive Income Of $-0.0584 For Period Ended 2008--1 ... - Investor Newswire (NASDAQ:CASI)
www.investornewswire.com - April 15 at 8:18 PM
clintongazette.com logoCasi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorted Shares Increased 22.79% After Market Selling - Clinton Financial (NASDAQ:CASI)
www.clintongazette.com - April 11 at 8:04 PM
News IconRevenue Update on CASI Pharmaceuticals Inc(NASDAQ:CASI) - Street Edition (NASDAQ:CASI)
www.streetedition.net - April 4 at 8:20 PM
News IconCasi Pharmaceuticals Incorporated (NASDAQ:CASI) Sellers Increased By 22.79% Their Shorts - Business Standard Tribune (NASDAQ:CASI)
www.standardtrib.com - April 1 at 7:59 PM
prnewswire.com logoCASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results - PR Newswire (press release) (NASDAQ:CASI)
www.prnewswire.com - March 30 at 7:54 PM
capitalcube.com logoCASI Pharmaceuticals, Inc. :CASI-US: Earnings Analysis: 2015 By the Numbers (NASDAQ:CASI)
www.capitalcube.com - March 30 at 11:51 AM
News IconMaking Moves: Gevo (NASDAQ:GEVO), CASI Pharmaceuticals (NASDAQ:CASI), Yahoo! Inc. (NASDAQ:YHOO), Itau ... - Property Mentor (NASDAQ:CASI)
www.propertymentorgroup.com - March 30 at 11:01 AM
kcregister.com logoWhy Need to Watch: CASI Pharmaceuticals, (NASDAQ:CASI), CPI Aerostructures (NYSEMKT:CVU), SunTrust Banks ... - KC Register (NASDAQ:CASI)
www.kcregister.com - March 30 at 11:01 AM
News IconH.C. Wainwright Maintains a Buy Rating on CASI Pharmaceuticals - Analyst Ratings (NASDAQ:CASI)
www.analystratings.com - March 29 at 12:30 PM
News IconNews Activity: CASI Pharmaceuticals (NASDAQ:CASI), Sumitomo Mitsui Financial Group (NYSE:SMFG), Invuity ... - Property Mentor (NASDAQ:CASI)
www.propertymentorgroup.com - March 28 at 12:59 PM

Social

CASI Pharmaceuticals (NASDAQ:CASI) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff